| Objective:To retrospectively study the efficacy and safety of recombinant human endostatin (rh-ES) combined with chemoradiotherapy (CRT) or chemotherapy (CT) in treatment of advanced malignancies.Methods:27 cases of advanced malignancies in Oncology Department of the First Affiliated Hospital of Chongqing Medical University from January 2010 to August 2013 were retrospectively analyzed. All 27 patients were treated with rh-ES combined with CT or CRT. The safety and changes of the quality of life(QOL) were evaluated after one cycle treatment,and the efficacy was evaluated after two cycles.Results:Among 23 evaluable cases for recent curative effect, the objective response rate (ORR) was 30.4%, and the disease control rate (DCR) was 78.3%. Among 18 cases of advanced non-small cell lung cancer (NSCLC), the median progression free survival (PFS) was 5.5 months, and the median overall survival (OS) was 12.0 months,1-year survival rate was 50.0%, and 2-year survival rate was 28.6%. For the quality of life (QOL) of all these patients,23 cases (85.2%) were improved or stable. The adverse reaction of G3/4 presented only 8 times.Conclusions:Rh-ES combined CT or CRT were effective and safe for advanced malignancies, and the quality of life could be improved or remained stable. Compared with other results of chemotherapy alone, the median PFS and 1-year survival rate in advanced NSCLC were higher, so it is worthy for further clinical application. |
PDF Full Text Request